Systemic sclerosis (scleroderma): A case of recovery of cardiomyopatby after vitamin E treatment

Minerva Cardioangiologica

Volumn 49, Issue 2, 2001, Pages 127-130

  Morelli, S ^a,b   Sgreccia, A ^a   Bernardo, M L ^a   Gurgo Di Castelmenardo, A ^a   Petrilli, A C ^a   De Leva, R ^a   Nuccio, F ^a   Calvieri, S ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Heart failure, congestive; Scleroderma, systemic; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT;

ARTICLE; CASE REPORT; CONGESTIVE HEART FAILURE; FEMALE; HUMAN; MIDDLE AGED; REMISSION; SYSTEMIC SCLEROSIS;

ANTIOXIDANTS; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MIDDLE AGED; REMISSION INDUCTION; SCLERODERMA, SYSTEMIC; VITAMIN E;

EID: 0035318321     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Gilliland BC. Systemic sclerosis (scleroderma). In: Fauci AS, Braunwald E, Isselbacher KJ, Wilson J, Martin JB, Kasper DL, Hauser SL, Longo DL, editors. Harrison's principles of internal medicine. 14th edition. New York: McGraw-Hill, 1998:1888-96.
2. Medsger TA Jr, Masi AT. Survival with scleroderma II. A life-table analysis of clinical and demographic factors in 358 male U.S. veteran patients. J Chronic Dis 1973;26:647-60.
3. Bunce TD, Black CM, Bruckdorfer KR. Systemic sclerosis, plasma antioxidant and lipids. Biochem Soc Trans 1995;23:274S.
4. Bruckdorfer KR, Hillary JB, Bunce T, Vancheeswaran R, Black CM. Increased susceptibility to oxidation of low-density lipoproteins isolated from patients with systemic sclerosis. Arthritis Rheum 1995;38:1060-7.
5. Herrick AL, Rieley F, Schonfield D, Hollis S, Braganza JM, Jayson MIV. Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis. J Rheumatol 1994;21:1477-83
6. Lau CS, O'Dowd A, Belch JJF. White blood cell activation in Raynaud's phenomenon of systemic sclerosis and vibration induced white finger syndrome. Ann Rheum Dis 1992;51:249-52.
7. Murrell DF. A radical proposal for the pathogenesis of scleroderma. J Am Acad Dermatol 1993;28:78-85.
8. Zangerle R, Wachter H, Fuchs D. Actived macrophages and radicals in scleroderma. J Am Acad Dermatol 1994;30:1045-7.
9. D'Angelo WA, Fries JF, Masi AT Shulman LE. Pathologic observations in systemic sclerosis (scleroderma): a study of fifty-eight autopsy cases and fifty-eight matched controls. Am J Med 1969;46:428-40.
10. Kaul N, Siveski-Iliskovic N, Thomas TP, Hill M, Khaper N, Singal PK. Probucol improves antioxidant activity and modulates development of diabetic cardiomyopathy. Nutrition 1995;11(Suppl):551.
11. Nordmann R, Ribiere C, Rouach H. Ethanol-induced lipid peroxidation and oxidative stress in extrahepatic tissues. Alcohol Alcohol 1990;25:231-7.
12. Siveski-Iliskovic N, Kaul N, Singal PK. Probucol promotes endogenoous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation 1994;89:2829-35.
13. Weglicki WB, Bloom S, Cassidy MM, Freedman AM, Atrakchi AH, Dickens BF. Antioxidants and the cardiomyopathy of Mg-deficiency. Am J Cardiovasc Pathol 1992;4:210-5.
14. Eubanks LE, McBurney EI, Galen W, Reed R. Linear scleroderma in children. Int J Dermatol 1996;35: 330-6.
15. Kahan A, Devaux JY, Amor B, Menkes CJ, Weber S, Nitenberg A et al. Nifedipine and thallium-201 myocardial perfusion in progressive systemic sclerosis. N Engl J Med 1986;314:1397-402.